Boehringer Ingelheim
Browse

Poster presented at EASL 2025 - Survodutide, a glucagon/ GLP-1 receptor dual agonist, in people with MASH with moderate-to advanced liver fibrosis (stage F2–F3): rationale and design of an event driven, multinational, randomised, placebo controlled, phase 3 trial (LIVERAGE™)

Download (330.57 kB)
poster
posted on 2025-05-15, 11:32 authored by Joern Schattenberg, Mazen Noureddin, Naim Alkhouri, Luiza Borowska, Daniel Mazo, Martina Brueckmann, Mandy Fraessdorf, Samina Hussain, Ramy Younes, Arun J. Sanyal

This poster was presented at EASL 2025

Funding

This study was sponsored by Boehringer Ingelheim. Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally.

History

Usage metrics

    Categories

    Keywords

    Liverage trialliver fibrosis (F2-F3)survodutideMASHMASLDliver fibrosisnon-invasive biomarkersphase 3 clinical trialdual agonist (GCGR/GLP-1R)hepatocyte survivalbiopsy-confirmed MASHELF scoreMRI-PDFFVCTEHbA1cliver stiffnessNAS (NAFLD Activity Score)

    Licence

    CC BY 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC